Exelixis taps into cancer antibody discoverer out of Sweden

Exelixis is doling out $25 million to snag rights to choose three targets found by BioInvent.

The California cancer drugmaker is linking arms with the Swedish biotech — both founded in the mid 90’s — to expand its suite of antibodies for immuno-oncology. BioInvent will offer up its cancer immunology and antibody biology chops and Exelixis will bring its antibody-drug conjugate tech to the table.